This study is looking at whether a type of special antibody called broadly neutralizing antibodies (bNAbs) is safe to use along with antiretroviral therapy (ART) in people who have been recently diagnosed with HIV. We also want to find out if these antibodies help control HIV better after people stop their regular medicine (ART), compared to those who didn’t get the antibodies.
This study wants to see if gut problems are worse in HIV+ men that have sex with men that have metabolic syndrome compared those without metabolic syndrome.
This study wants to see if gut problems are worse in men with and without HIV that have sex with men who have metabolic syndrome compared to those without metabolic syndrome. We are looking for men that do not have HIV.
To describe the pharmacokinetics of GLE and PIB initiated in pregnant women with hepatitis C and to compare the PK to historical data in non-pregnant female adults with hepatitis C To describe the safety of GLE/PIB initiated in pregnant women with hepatitis C while on treatment and through 10 weeks postpartum (or 20 weeks post-treatment initiation)